Back

Semaglutide or tirzepatide in heart failure across ejection fraction phenotypes: a new-user, active-comparator target trial emulation

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: HFpEF: challenges in diagnostics and treatment Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Elias Rawish

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)

6 More presentations in this session

Presentation thumbnail
Recovered versus preserved ejection fraction in heart failure: long-term outcomes and the role of sustained remission
Doctor E. Tartaglia (Modena, IT)
Abstract
Presentation thumbnail
Unrecognized heart failure with preserved ejection fraction in COPD: phenotyp-ing a prospective cohort using the HFA-PEFF score
Doctor L. Duus (Copenhagen, DK)
Abstract
Presentation thumbnail
Treatment adherence and risk prediction in HFpEF: a machine learning and structural equation modeling study
Doctor Q. Su (Lanzhou, CN)
Abstract
Presentation thumbnail
Metabolomics integrated with transcriptomics analysis: identifying biomarkers for 4-year all-cause mortality in heart failure patients with preserved ejection fraction in the Chinese Han population
Miss Y. Li (CN)
Abstract
Presentation thumbnail
Prognostic impact of the HFA-PEFF and H2FPEF scores in patients with sick sinus syndrome
Doctor S. Mishima (Kamogawa, JP)
Abstract

Access the full session

Session thumbnail
HFpEF: challenges in diagnostics and treatment

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of semaglutide in patients with obesity-related heart failure: a meta-analysis of randomized clinical trials
3 April 2025
thumbnail
Congress Presentation
Association between initiation of sacubitril/valsartan and improved left ventricular ejection fraction in the real world
30 June 2021
thumbnail
Congress Presentation
Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
21 May 2022
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources